Login
Register
Reset Password
Publish & Distribute
Publishing Solutions
Distribution Solutions
Subjects
Architecture and Design
Arts
Business and Economics
Chemistry
Classical and Ancient Near Eastern Studies
Computer Sciences
Cultural Studies
Engineering
General Interest
Geosciences
History
Industrial Chemistry
Jewish Studies
Law
Library and Information Science, Book Studies
Life Sciences
Linguistics and Semiotics
Literary Studies
Materials Sciences
Mathematics
Medicine
Music
Pharmacy
Philosophy
Physics
Social Sciences
Sports and Recreation
Theology and Religion
Publications
Journals
Books
Proceedings
Publishers
Blog
Contact
Search
EUR
USD
GBP
English
English
Deutsch
Polski
Español
Français
Italiano
Cart
Home
Journals
Bulletin of Medical Sciences
Volume 95 (2022): Issue 2 (December 2022)
Open Access
Therapeutic importance, general and endocrine adverse effects of immune checkpoint inhibitors I: mechanism of action and therapeutic use
Imre Zoltán Kun
Imre Zoltán Kun
,
Ildikó Kun
Ildikó Kun
,
Margit Hadnagy
Margit Hadnagy
and
Melinda Kolcsár
Melinda Kolcsár
| Jun 07, 2024
Bulletin of Medical Sciences
Volume 95 (2022): Issue 2 (December 2022)
About this article
Previous Article
Next Article
Abstract
References
Authors
Articles in this Issue
Preview
PDF
Cite
Share
Published Online:
Jun 07, 2024
Page range:
145 - 166
DOI:
https://doi.org/10.2478/orvtudert-2022-0010
Keywords
immune checkpoint inhibitors
,
ipilimumab
,
nivolumab
,
pembrolizumab
© 2022 Imre Zoltán Kun et al., published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.